GLP-1 patent drops spark counterfeit rise. Cypheme urges generic drug makers to adopt AI authentication standards

Paris, France May 21, 2026 (EMWNews.com) – Important patents for semaglutide-based GLP-1 drugs are beginning to expire, which is accelerating the growth of the global generic drug market. Cypheme today called upon manufacturers to adopt AI-powered authentication standards to safeguard supply chains and protect patient safety. The announcement comes alongside ongoing warnings from regulators, including the U.S. Food and Drug Administration and Australia’s Therapeutic Goods Administration, about fake GLP-1 products entering legitimate distribution channels.

As the generic GLP-1 market scales globally, the absence of a universal authentication standard is creating a critical vulnerability: counterfeit medicines that are often visually indistinguishable from legitimate products. According to the World Health Organization, an estimated 1 in 10 medical products in low- and middle-income countries is substandard or falsified, underscoring the scale of the global counterfeit drug crisis. Regulatory agencies have also increased import alerts and seizures tied to falsified pharmaceuticals, signaling growing pressure on supply chain integrity as demand surges.

Cypheme is addressing this challenge with its proprietary Noise Print technology, positioning it as a “Digital Certificate of Origin” for pharmaceutical packaging. Applied directly to product labels or packaging, Noise Print enables instant verification using a standard smartphone camera; no specialized hardware required. The company argues that for legitimate generic manufacturers, verifiable packaging is not a regulatory burden but a competitive advantage by providing a clear, scalable way to differentiate trusted products in an increasingly crowded and risk-prone market.

“The generic pharmaceutical industry is reaching a defining moment,” said Hugo Garcia-Cotte, CEO of Cypheme. “The manufacturers who build trust through transparency will define the category. Those who don’t will be indistinguishable from the counterfeiters they’re competing against.”

Cypheme also announced that it is actively partnering with generic GLP-1 manufacturers to pilot authentication standards ahead of the anticipated 2026-2027 market expansion. These pilot programs aim to establish a new baseline for product verification, one that aligns with regulatory expectations while reinforcing consumer confidence at scale.

About Cypheme

Cypheme is a global leader in AI-powered anti-counterfeiting technology, providing brands and governments with advanced tools to verify product authenticity and combat fraud. Its patented Noise Print technology enables instant, smartphone-based authentication and delivers actionable insights through geolocation intelligence and data analytics. Endorsed by international institutions and trusted across industries, including pharmaceuticals, Cypheme helps organizations protect revenue, strengthen supply chains, and ensure consumer safety.

For more information, visit: https://www.cypheme.com/

Media Contact:

Cypheme Communications

Email: [email protected]

Address: 5 Parvis Alan Turing, 75013 Paris, France